Upgrade to SI Premium - Free Trial

RBC Capital Reiterates Underperform Rating on Pfizer (PFE)

April 7, 2026 8:54 AM
RBC Capital analyst Trung Huynh reiterated an Underperform rating and $25.00 price target on Pfizer (NYSE: PFE).The analyst commented: "Mixed ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments